The brain melanocortin system, sympathetic control, and obesity hypertension

Physiology

Volumn 29, Issue 3, 2014, Pages 196-202

  Da Silva, Alexandre A ^a   Do Carmo, Jussara M ^a   Wang, Zhen ^a   Hall, John E ^a  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MELANOCORTIN;

ADRENERGIC SYSTEM; ANIMAL; BRAIN; CARDIOVASCULAR SYSTEM; HUMAN; HYPERTENSION; METABOLISM; OBESITY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; BRAIN; CARDIOVASCULAR SYSTEM; HUMANS; HYPERTENSION; MELANOCORTINS; OBESITY; SYMPATHETIC NERVOUS SYSTEM;

EID: 84900824252     PISSN: 15489213     EISSN: 15489221     Source Type: Journal    
DOI: 10.1152/physiol.00061.2013     Document Type: Review

References (57)

1. Armitage JA, Burke SL, Prior LJ, Barzel B, Eikelis N, Lim K, Head GA. Rapid onset of renal sympathetic nerve activation in rabbits fed a high-fat diet. Hypertension 60: 163-171, 2012.
2. Balthasar N, Dalgaard LT, Lee CE, Yu J, Funahashi H, Williams T, Ferreira M, Tang V, McGovern RA, Kenny CD, Christiansen LM, Edelstein E, Choi B, Boss O, Aschkenasi C, Zhang CY, Mountjoy K, Kishi T, Elmquist JK, Lowell BB. Divergence of melanocortin pathways in the control of food intake and energy expenditure. Cell 123: 493-505, 2005.
3. Bariohay B, Roux J, Tardivel C, Trouslard J, Jean A, Lebrun B. Brain-derived neurotrophic factor/tropomyosin-related ki-nase receptor type B signaling is a downstream effector of the brainstem melanocortin system in food intake control. Endocrinology 150: 2646-2653, 2009.
4. Carlyle M, Jones OB, Kuo JJ, Hall JE. Chronic cardiovascular and renal actions of leptin-role of adrenergic activity. Hypertension 39: 496-501, 2002.
5. Corander MP, Fenech M, Coll AP. How melanocortin action in the brain modulates body weight, blood pressure, and ischemic damage. Circulation 120: 2260-2268, 2009.
6. da Silva AA, do Carmo J, Dubinion J, Hall JE. The role of the sympathetic nervous system in obesity-related hypertension. Curr Hypertens Rep 11: 206-211, 2009.
7. da Silva AA, do Carmo JM, Kanyicska B, Dubinion J, Brandon E, Hall JE. Endogenous melanocortin system activity contributes to the elevated arterial pressure in spontaneously hypertensive rats. Hypertension 51: 884-890, 2008.
8. da Silva AA, Kuo JJ, Hall JE. Role of hypothalamic melano-cortin 3/4-receptors in mediating chronic cardiovascular, renal, and metabolic actions of leptin. Hypertension 43: 1312- 1317, 2004.
9. Davy KP, Hall JE. Obesity, and hypertension: two epidemics or one? Am J Physiol Regul Integr Comp Physiol 286: R803-R813, 2004.
10. Davy KP, Orr JS. Sympathetic nervous system behavior in human obesity. Neurosci Biobehav Rev 33: 116-124, 2009.
11. Department of Health, and Human Services, Center for Disease Control and Prevention. Obesity and overweight trends in the U.S., 2011 (Online). Atlanta, GA: Center for Disease Control. http://www.cdc.gov/nccdphp/dnpa/obesity/trend/index.htm.
12. do Carmo JM, Bassi M, da Silva AA, Hall JE. Systemic but not central nervous system nitric oxide synthase inhibition exacerbates the hypertensive effects of chronic melanocortin-3/4 receptor activation. Hypertension 57: 428-434, 2011.
13. do Carmo JM, da Silva AA, Cai Z, Lin S, Dubinion JH, Hall JE. Control of blood pressure, appetite, and glucose by leptin in mice lacking leptin receptors in proopiomelanocortin neurons. Hypertension 57: 918-926, 2011.
14. do Carmo JM, da Silva AA, Rushing JS, Hall JE. Activation of the central melanocortin system contributes to the increased arterial pressure in obese Zucker rats. Am J Physiol Regul Integr Comp Physiol 302: R561-R567, 2012.
15. do Carmo JM, da Silva AA, Rushing JS, Pace B, Hall JE. Differential control of metabolic and cardiovascular functions by melanocortin-4 receptors in proopi-omelanocortin neurons. Am J Physiol Regul Integr Comp Physiol 305: R359 -R368, 2013.
16. Dubinion JH, da Silva AA, Hall JE. Enhanced blood pressure and appetite responses to chronic central melanocortin-3/4 receptor blockade in dietary-induced obesity. J Hyper-tens 28: 1466-1470, 2010.
17. Greenfield JR, Miller JW, Keogh JM, Henning E, Sat-terwhite JH, Cameron GS, Astruc B, Mayer JP, Brage S, See TC, Lomas DJ, O'Rahilly S, Farooqi IS. Modulation of blood pressure by central melanocortinergic pathways. N Engl J Med 360: 44 -52, 2009.
18. Guyton AC. The surprising kidney-fluid mechanism for pressure control: its infinite gain! Hypertension 16: 425-430, 1990.
19. Hall JE. The kidney, hypertension, obesity. Hypertension 41: 625-633, 2003.
20. Hall JE, Crook ED, Jones DW, Wofford MR, Dub-bert PM. Mechanisms of obesity-associated cardiovascular and renal disease. Am J Med Sci 324: 127-137, 2002.
21. Hall JE, da Silva AA, do Carmo JM, Dubinion J, Hamza S, Munusamy S, Smith G, Stec DE. Obesity-induced hypertension: role of sympathetic nervous system, leptin, and melanocortins. J Biol Chem 285: 17271-17276, 2010.
22. Hallersund P, Sjöström L, Olbers T, Lönroth H, Jacobson P, Wallenius V, Näslund I, Carlsson LM, Fändriks L. Gastric bypass surgery is followed by lowered blood pressure and increased diuresis: long term results from the Swedish Obese Subjects (SOS) study. PLos One 7: e49696, 2012.
23. Humphreys MH, Ni XP, Pearce D. Cardiovascular effects of melanocortins. Eur J Pharmacol 660: 43-53, 2011.
24. Iwasa M, Kawabe K, Sapru HN. Activation of melanocortin receptors in the intermediolateral cell column of the upper thoracic cord elicits tachycardia in the rat. Am J Physiol Heart Circ Physiol 305: H885-H893, 2013.
25. Kassab S, Kato T, Wilkins FC, Chen R, Hall JE, Granger JP. Renal denervation attenuates the sodium retention and hypertension associated with obesity. Hypertension 25: 893-897, 1995.
26. Kuo JJ, da Silva AA, Hall JE. Hypothalamic mela-nocortin receptors and chronic regulation of arterial pressure and renal function. Hypertension 41: 768-774, 2003.
27. Kuo JJ, da Silva AA, Tallam LS, Hall JE. Role of adrenergic activity in pressure responses to chronic melanocortin receptor activation. Hypertension 43: 370-375, 2004.
28. Li P, Cui BP, Zhang LL, Sun HJ, Liu TY, Zhu GQ. Melanocortin 3/4 receptors in paraventricular nucleus modulate sympathetic outflow and blood pressure. Exp Physiol 98: 435-443, 2013.
29. Mark AL. Weight reduction for the treatment of obesity-associated hypertension: nuances and challenges. Curr Hypertens Rep 9: 368-372, 2007.
30. Mark AL. Selective leptin resistance revisited. Am J Physiol Regul Integr Comp Physiol 305: R566- R581, 2013.
31. Martinelli CE, Keogh JM, Greenfield JR, Henning E, van der Klaauw AA, Blackwood A, O'Rahilly S, Roelfsema F, Camacho-Hübner C, Pijl H, Farooqi IS. Obesity due to melanocortin 4 receptor (MC4R) deficiency is associated with increased linear growth and final height, fasting hyperinsu-linemia, and incompletely suppressed growth hormone secretion. J Clin Endocrinol Metab 96: E181-E188, 2011.
32. Nicholson JR, Peter JC, Lecourt AC, Barde YA, Hofbauer KG. Melanocortin-4 receptor activation stimulates hypothalamic brain-derived neurotrophic factor release to regulate food intake, body temperature and cardiovascular function. J Neuroendocrinol 19: 974-982, 2007.
33. Nogueiras R, Williams LM, Dieguez C. Ghrelin: new molecular pathways modulating appetite and adiposity. Obes Facts 3: 285-292, 2010.
34. Overton JD, Leibel RL. Mahoganoid and mahogany mutations rectify the obesity of the yellow mouse by effects on endosomal traffic of Mc4R protein. J Biol Chem 286: 18914-18929, 2011.
35. Ozata M, Ozdemir IC, Licinio J. Human leptin deficiency caused by a missense mutation: multiple endocrine defects, decreased sympathetic tone, and immune system dysfunction indicate new targets for leptin action, greater central than peripheral resistance to the effects of leptin, and spontaneous correction of leptin-mediated defects. J Clin Endocrinol Metab 10: 3686-3695, 1999.
36. Pavia JM, Pavia JM, Schiöth HB, Morris MJ. Role of MC4 receptors in the depressor and brady-cardic effects of alpha-MSH in the nucleus tractus solitarii of the rat. Neuroreport 14: 703-707, 2003.
37. Rahmouni K, Haynes WG, Morgan DA, Mark AL. Role of melanocortin-4 receptors in mediating the renal sympathoactivation to leptin and insulin. J Neurosci 23: 5998-6004, 2003.
38. Rossi J, Balthasar N, Olson D, Scott M, Ber-glund E, Lee CE, Choi MJ, Lauzon D, Lowell BB, Elmquist JK. Melanocortin-4 receptors expressed by cholinergic neurons regulate energy balance and glucose homeostasis. Cell Metab 13: 195-204, 2011.
39. Shariat-Madar B, Kolte D, Verlangieri A, Shariat-Madar Z. Prolylcarboxypeptidase (PRCP) as new target for obesity treatment. Diabetes Metab Syndr Obes 3: 67-78, 2010.
40. Sjöström CD, Peltonen M, Wedel H, Sjöström L. Differentiated long-term effects of intentional weight loss on diabetes and hypertension. Hypertension 36: 20-25, 2000.
41. Sohn JW, Harris LE, Berglund ED, Liu T, Vong L, Lowell BB, Balthasar N, Williams KW, Elmquist JK. Melanocortin 4 receptors reciprocally regulate sympathetic and parasympathetic pregangli-onic neurons. Cell 152: 612-619, 2013.
42. Spradley Ft Palei AC, Granger JP. Obese mela-nocortin-4 receptor-deficient rats exhibit augmented angiogenic balance and vasorelaxation during pregnancy. Physiol Rep 1: e00081, 2013.
43. Stevens VJ, Obarzanek E, Cook NR, Lee IM, Ap-pel LJ, Smith West D, Milas NC, Mattfeldt-Beman M, Belden L, Bragg C, Millstone M, Raczynski J, Brewer A, Singh B, Cohen J. Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II. Ann Intern Med 134: 1-11, 2001.
44. Straznicky NE, Eikelis N, Lambert EA, Esler MD. Mediators of sympathetic activation in metabolic syndrome obesity. Curr Hypertens Rep 10: 440-447, 2008.
45. Tai MH, Weng WT, Lo WC, Chan JY, Lam HC, Tseng CJ. Role of nitric oxide in alpha-melano-cyte-stimulating hormone-induced hypotension in the nucleus tractus solitarii of the spontaneously hypertensive rats. J Pharmacol Exp Ther 321: 455-461, 2007.
46. Tallam LS, da Silva AA, Hall JE. Melanocortin-4 receptor mediates chronic cardiovascular and metabolic actions of leptin. Hypertension 48: 58-64, 2006.
47. Tallam LS, Kuo JJ, da Silva AA, Hall JE. Cardiovascular, renal, and metabolic responses to chronic central administration of agouti-related peptide. Hypertension 44: 853-858, 2004.
48. Tallam LS, Stec DE, Willis MA, da Silva AA, Hall JE. Melanocortin-4 receptor-deficient mice are not hypertensive or salt-sensitive despite obesity, hyperinsulinemia, and hyperleptinemia. Hypertension 46: 326-332, 2005.
49. Tao YX. The melanocortin-4 receptor: physiology, pharmacology and pathophysiology. Endocr Rev 31: 506-543, 2010.
50. Vaisse C, Clement K, Durand E, Hercberg S, Guy-Grand B, Froguel P. Melanocortin-4 receptor mutations are a frequent and heterogeneous cause of morbid obesity. J Clin Invest 106: 253-262, 2000.
51. Wallingford N, Perroud B, Gao Q, Coppola A, Gyengesi E, Liu ZW, Gao XB, Diament A, Haus KA, Shariat-Madar Z, Mahdi F, Wardlaw SL, Sch-maier AH, Warden CH, Diano S. Prolylcarboxy-peptidase regulates food intake by inactivating alpha-MSH in rodents. J Clin Invest 119: 2291-2303, 2009.
52. Ward KR, Bardgett JF, Wolfgang L, Stocker SD. Sympathetic response to insulin is mediated by melanocortin 3/4 receptors in the hypothalamic paraventricular nucleus. Hypertension 57: 435-441, 2011.
53. Wilson PW, D'Agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med 162: 1867-1872, 2002.
54. Wofford MR, Anderson DC, Brown CA, Jones DW, Miller ME, Hall JE. Antihypertensive effect of alpha and beta adrenergic blockade in obese and lean hypertensive subjects. Am J Hypertens 14: 694-698, 2001.
55. Yosten GL, Samson WK. Nesfatin-1 exerts cardiovascular actions in brain: possible interaction with the central melanocortin system. Am J Physiol Regul Integr Comp Physiol 297: R330- R336, 2009.
56. Yosten GL, Samson WK. The anorexigenic and hypertensive effects of nesfatin-1 are reversed by pretreatment with an oxytocin receptor antagonist. Am J Physiol Regul Integr Comp Physiol 298: R1642-R1647, 2010.
57. Yosten GL, Pate AT, Samson WK. Neuronostatin acts in brain to biphasically increase mean arterial pressure through sympatho-activation followed by vasopressin secretion: the role of melanocor-tin receptors. Am J Physiol Regul Integr Comp Physiol 300: R1194-R1199, 2011.